AstraZeneca

AstraZeneca is a global biopharmaceutical company founded in 1999, developing and delivering therapies across oncology, biopharmaceuticals, respiratory and rare diseases. Its commercial portfolio comprises 16 blockbuster medicines, and its research pipeline contains 197 projects in development, with a stated aim of launching 20 new medicines by 2030. The company invests billions annually in research and development.

Technical work spans precision medicine, next-generation therapeutics, cell therapies, data science and artificial intelligence, alongside pharmaceutical R&D more broadly. Research is concentrated at six strategic R&D centres located in Cambridge (UK), Gothenburg (Sweden), Gaithersburg and Boston (USA) and Shanghai and Beijing (China), with corporate roots in the United Kingdom and Sweden.

The company describes itself as values-driven since the 1999 merger that formed it, operating on a principle of "following the science" and a patient-first commitment. It characterises its culture as one of sustained pursuit of breakthrough therapies and of bold, long-dated scientific goals.